Kornimate/medical-research-clean huggingface dataset:
comparison of an non-ablative fractional 1565nm vs. an ablative 2940-nm fractional er laser for the treatment of androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: laser sources have established their potential effect in inducing hair regrowth. no study has compared the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (er: yag) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (aga).

the investigators performed a prospective study between to compare the efficacy and safety of ablative fractional 2940-nm erbium yttrium aluminum garnet (er: yag) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (aga). the efficacy of the two therapies was evaluated by the investigator's global assessment (iga) scores and the patient's likert satisfaction scale at week 12 and week 24. changes in total, terminal and villous hair count, total and terminal hair diameter, and aga grade were also recorded. adverse events were evaluated at each follow-up.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years;； * clinical diagnosis of aga； * aga diagnosis was evaluated following norwood hamilton grade ii-v criteria； * no previous laser treatments for aga in the past six months before enrollment； * willingness to provide pictures and follow-up studies. exclusion criteria: * if presented with severe diseases of internal organs, eyes, or skin; * inflammation, infection, or unhealed wounds on the skin around the site of treatment on the head; * systematic treatment with corticosteroids or other immunosuppressants and immunomodulators in the past 3 months
tace plus sorafenib versus tace alone for recurrent intermediate hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Sorafenib; Transarterial Chemoembolization

Summary: the study is a multicenter phase iii randomized trial. the purpose is to investigate both the efficacy and safety of transarterial chemoembolization (tace) plus sorafenib versus tace alone for recurrent intermediate hepatocellular carcinoma patients.

the trial will recruit 162 patients with recurrent intermediate hcc, and they will be randomized (1:1) into two groups (tace+sorafenib group, tace group). patients in tace+sorafenib group will receive tace one day following oral sorafenib (initial dose: 400mg bid). patients in the tace group will receive tace alone.

Eligibility criteria:
inclusion criteria: 1. age: 18-75 years; 2. diagnosed as hcc based on the american association for the study of liver diseases 2018 guideline on liver cancer diagnosis; 3. initial tumor recurrence following curative surgical resection (r0 hepatectomy) (two to three lesions with at least one lesion \>3 cm in diameter or more than three lesions of any diameter). tumor burden ≤ 50% and no distant metastasis and macroscopic vascular invasion; 4. histologically confirmed microvascular invasion in the specimen slices of surgically removed primary tumor; 5. eastern cooperative oncology group scoring 0-1; 6. child-pugh a class; 7. at least 3 months of life expectancy; 8. adequate hematologic, hepatic and renal function: absolute neutrophil count ≥ 1.5x10\^9/l, platelet ≥ 60 x10\^9/l, hb ≥ 90g/l, albumin ≥ 30g/l, total bilirubin ≤ 1.5 x upper limit of normal (uln) , alt \< 5×uln, ast \< 5×uln, alkaline phosphatase \< 4×uln, extended prothrombin time not exceeding 6s of uln, creatine\<1.5×uln. exclusion criteria: 1. have lesions which are diffuse or can not be evaluated via imaging. tumor burden\>50%; 2. have a history of hepatic encephalopathy, refractory ascites, severe esophageal and gastric varices or variceal bleeding and obstructive jaundice; 3. have contraindications for tace; 4. have metastasis in central nervous system; 5. allergic to intravenous contrast agents; 6. pregnant or breastfeeding women, or expecting to conceive or father children within two years; 7. infection of hiv, known syphilis requiring treatment; 8. have a known history of prior invasive malignancies within 5 years before enrolment; 9. patients with allotransplantation; 10. severe dysfunction involving heart, kidney or other organs; 11. severe active clinical infection which is over grade 2 based on nci-ctc version 4; 12. patients with mental disorders which may impact informed consent; 13. unable to orally take drugs; 14. participating other clinical drug trials 12 months before enrolment.
bacterium: study for a machine-learning-based model to predict bloodstream infections

Conditions: Infection, Bloodstream

Summary: an increase of healthcare-associated infections caused by multidrug- resistant organisms (mrdo) is currently observed. one of the main causes of the emergence of a mdro infection is an overuse of antibiotics. therefore, saving useless antibiotic treatment is currently a priority from a public health point of view. the evaluation of the risk of having a bloodstream infection will allow both activating faster treatment decisions (when the risk is significantly high) or to save useless resources in terms of diagnostic tests and treatments, also limiting the potential for side effects (when the risk is significantly low).


Eligibility criteria:
inclusion criteria: 1. adult patients hospitalized at the gemelli polyclinic foundation 2. having at least one performed blood culture 3. starting an antibiotic therapy exclusion criteria: 1. blood cultures with contaminants 2. \<18 years old 3. died after less than 48 hours from blood cultures positivity
defibrotide for patients with hepatic veno-occlusive disease: a treatment ind study

Conditions: Hepatic Veno-Occlusive Disease

Summary: single arm, open-label study to provide defibrotide to patients diagnosed with vod. defibrotide is no longer available though the emergency use ind mechanism (also known as compassionate use, or single patient named use). this protocol is the only mechanism by which defibrotide can be made available to patients in the u.s.


Eligibility criteria:
inclusion criteria: entry criteria include the following: 1. clinical diagnosis of vod, made by baltimore criteria, modified seattle criteria, or biopsy proven: 1.1 baltimore criteria- bilirubin ≥2 mg/dl and at least 2 of the following clinical findings: * ascites (radiographic or physical exam) * weight gain of ≥5% compared to the day of conditioning-- if this value is not available, the weight on the date of admission to the sct unit may be used) * hepatomegaly; increased over baseline. 1.2 modified seattle criteria: at least two of the following * bilirubin ≥2 mg/dl * ascites (radiographic or physical exam) and/or weight gain ≥5% above baseline weight (defined as weight on the first day of conditioning- if this value is not available, the weight on the date of admission to the sct unit may be used) * hepatomegaly increased over baseline 1.3 patients that do not meet the baltimore criteria or modified seattle criteria and have biopsy proven vod are eligible. 2. patient must also provide written informed consent. exclusion criteria: * use of any medication which increases the risk of hemorrhage is disallowed. use of heparin or other anticoagulants is disallowed within 12 hours unless being used for routine central venous line management, fibrinolytic instillation for central venous line occlusion, intermittent dialysis or ultrafiltration of cvvh. * clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring \> 15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and requiring \> 300cc of packed red blood cells/24 hours, or an adult patient weighing 70 kg and requiring \>3 units of packed red blood cells/24 hours) to replace blood loss, or bleeding from a site which in the investigator's opinion constitutes a potential life-threatening source (e.g. pulmonary hemorrhage or cns bleeding), irrespective of amount of blood loss, at any point from the date of sct through the date of severe vod diagnosis. * hemodynamic instability as defined by a requirement for multiple pressors, or inability to maintain mean arterial pressure (for children: to maintain mean arterial pressure within 1 standard deviation of age-adjusted levels) with single pressor support. * woman who are pregnant.

Keywords: vod
echinaforce covid-19 shedding study

Conditions: COVID-19 Respiratory Infection; SARS-CoV2 Infection

Summary: respiratory viruses pose a permanent threat to humans and society as demonstrated by the current covid-19 pandemic. novel drugs and vaccines provide a means for controlling illness. infections and symptomatic presentation of illness may be reduced, but it remains to be determined to which extent viral shedding and transmission (e.g. by silent transmitters) can be controlled. lack of such activity may result in continuing viral spread by assumed healthy but asymptomatic spreaders. echinacea is an established and readily-accessible product with demonstrated in vitro antiviral activity (including coronaviruses). this study aims to estimate the potential of different echinacea formulations (head-to-head) to reduce concentration infectivity and shedding of sars-cov-2 under in vivo conditions.


Eligibility criteria:
inclusion criteria: * age 12 - 75 years. * written informed consent. * ability and willingness to give oropharyngeal swab samples. * positive pre-screening sars-cov-2 rt-pcr virus test with an above threshold viral load as per qpcr (cq ≤ 27). exclusion criteria: * ≥76 years * \<12 years. * participation in another clinical study in the past 30 days or planned during study conduct. * severe covid19 * intake of antimicrobial, antiviral, immune suppressive substances. * surgical intervention in the 3 months prior enrolment * known diabetes mellitus. * known and medicated atopy or asthma. * cystic fibrosis, bronchopulmonary dysfunction, copd. * known immune system disorders and degenerative disorders (autoimmune disorders, aids, leukemia, lymphoma, myeloma). * known metabolic or resorption disorders. * known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidney insufficiency). * serious health conditions (limited general condition, auto-immune diseases, tumorous diseases, neurological disorders or serious covid-19) * known allergies to plants of the compositae family (e.g. chamomile or dandelion) or to one of the compounds in the investigational product * known pregnancy.

Keywords: sars-cov2 infectivity viral load reduction antiviral treatment oropharynx throat
impact of infectious diseases consultation on vaccination coverage among people waiting for a kidney transplant at the clermont-ferrand hospital

Conditions: Kidney Transplantation

Summary: solid-organ transplant patients are at increased risk of infectious diseases. among this population, infectious diseases may be life-threatening or lead to graft rejection. their prevention is an important challenge. despite specific national recommendations, vaccination is underutilized. that is why we propose a dedicated infectious diseases consultation during pre-kidney transplantation assessment.

the main objective of this study is to impove vaccine coverage before kidney transplantation. enrollment was based on the waiting list for a kidney transplant. patients newly listed are invited to participate by the transplant team (nephrology department) ; for those that are already registered, a notification letter is sent to their home. all patients included must : * complete a health questionnaire * take a blood test at day 0 : viral, bacterial and parasitic serologies, quantiferon-tb * take a chest x-ray and dental panoramic patients randomized in interventional group will be seen in specific infectious diseases consultation at clermont ferrand hospital. a letter of recommendations is sent to nephrologist for patients randomized in group control. the primary study endpoint (immunization coverage) is evaluated at 6 months.

Eligibility criteria:
inclusion criteria: * patient over 18 * on the waiting list for kidney transplantation at clermont-ferrand * free and informed consent * affiliation to a social security system exclusion criteria: * patient under 18 * protected adults (individuals under guardianship by court order * pregnant and nursing women * prior graft (solid organs or hematopoietic stem cells) * absence of consent

Keywords: immunization coverage transplant recipient transplantation, kidney infectious disease medicine
relations between atherogenic index of plasma-glucose metabolism

Conditions: Diabetes Mellitus Risk

Summary: in this study, the investigators aimed to find out whether there is any association between the atherogenic index of plasma with the glucose metabolism.in this respect, apart from the well-known diabetic risk factors, the investigators purposed to reveal new ones.

atherogenic index of plasma (aip) is a relatively new index and a predictor of cardiovascular risk. aip has been shown to be associated with impaired glucose metabolism. this study aimed to evaluate the relationship between aip and parameters of glucose metabolism. methods: this observational study involved 448 healthy individuals who were at risk for diabetes. they were sent to hospital for diabetes check. according to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the american diabetes association (ada). the association between the diabetes group, aip and parameters of glucose metabolism was analyzed. the accuracy of registry data compatible with medical records. statistical analyses were carried out using the statistical package for social sciences, windows version 15.0 (spss, chicago, illinois, usa). descriptive statistics for each variable were determined. normality of the data distribution was assessed with the kolmogorov-smirnov test. for continuous variables, non-parametric statistics (mann-whitney or kruskal-wallis), and parametric statistics (t-test, anova analysis) were used as appropriate. statistically significant differences between the groups were determined by the chi-square test for categorical variables. associations between the variables were explored using the pearson correlation and spearman's rho (for data that was not normally distributed). linear regression analysis with backward elimination was also performed to define variables associated with aip.

Eligibility criteria:
inclusion criteria: * all the participants were previously healthy, aged between 18 and 80 years, and were at risk for diabetes according to new criteria provided by the american diabetes association. exclusion criteria: * individuals with a history of chronic medical diseases and those who reported current use of any medication were excluded from the study
magnetic resonance image verified early response to certolizumab pegol in subjects with active rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: phase iiib study to determine early response to certolizumab pegol (czp) with magnetic resonance imaging (mri) score outcome measures in rheumatoid arthritis (ra) clinical trials (omeract) ra mri scoring system (ramris) in subjects with ra.

to identify the efficacy of certolizumab pegol (czp) on synovitis in dynamic mri parameters; to make the correlation between european league against rheumatism (eular), american college of rheumatology (acr)p, disease activity score-28 (das 28) responses, and digital xray (dxr) assessment with reduction of synovitis.

Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of adult-onset rheumatoid arthritis (ra) of at least 3 months duration but no longer than 15 years * subjects with an active adult rheumatoid arthritis disease * subjects who have been on disease-modifying anti-rheumatic drug (dmard) therapy for at least 12 weeks exclusion criteria: * subject must not have a secondary, non-inflammatory type of musculoskeletal condition (eg, osteoarthritis or fibromyalgia) that in the investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of rheumatoid arthritis (ra) * subject must not have a diagnosis of any other inflammatory arthritis (eg, psoriatic arthritis or ankylosing spondylitis) * subject must not have a history of an infected joint prosthesis at any time with prosthesis still in situ * subject must not have received more than 1 biological agent * subject must not have a history of lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time * subject with known tuberculosis (tb) disease, high risk of acquiring tb infection or latent tb infection * subject must not have a known hypersensitivity to any components of the investigational medicinal product * subject must not have contraindications for magnetic resonance image (mri) and contrast agent * subject must not have any other condition which, in the investigator's judgement, would make them unsuitable for inclusion in the study

Keywords: cimzia® cdp870 czp certolizumab pegol rheumatoid arthritis mri
percutaneous needle tenotomy (pnt) versus platelet rich plasma (prp) with pnt in the treatment of chronic tendinosis

Conditions: Chronic Tendinopathy

Summary: tendinopathy is a clinical syndrome of chronic pain and tendon degeneration that impairs a person's ability to perform daily activities and recreation. traditional conservative treatments include activity modification, exercises, ice/heat, and medications and corticosteroid injection. a newer treatment is percutaneous needle tenotomy (pnt), in which the affected area is repetitively needled to disrupt pathological tissue and induce bleeding. this turns a nonhealing chronic injury into an acute injury with enhanced healing capability. another is platelet rich plasma (prp), whereby patients' own platelets are injected into the affected area, also activating growth factors. there has been promising research in these tendinopathy treatments but more research is needed. the investigators plan to expand on prior studies to identify a reproducible and efficacious treatment for chronic tendinopathy to reduce pain and improve function and quality of life. our goal in this study is to assess the efficacy of ultrasound guided (usg) pnt versus pnt with peritendinous prp as a treatment for chronic tendinopathy.


Eligibility criteria:
inclusion criteria: * aged 18-100 years * pain (≥ 5/10 pain on the vas) that is a direct result of tendinosis as determined by history of injury and study team member physician's best judgment and review of medical records, imaging studies, etc. * tendinosis will be confirmed by clinical and ultrasonographic examination by the pi * ≥3 months of pain after injury that has failed conservative treatments or after corticosteroid (csi) (must be 3 months after csi to avoid theoretical tendon rupture) exclusion criteria: * taking coumadin or other anti-coagulant or anti-platelet medication * known coagulopathy or bleeding dyscrasia * current or recent fluoroquinolone prescription * prior pnt or prp for the affected tendon(s) * known systemic illness such as vasculitis, an autoimmune or an inflammatory disease, or uncontrolled diabetes * presence of other musculoskeletal injury or tendon rupture in the region * currently are or plan to become pregnant during the study. * patients taking aspirin or nsaids are not excluded.

Keywords: chronic tendinopathy platelet rich plasma tendonitis percutaneous tendon tenotomy pain shoulder knee ankle foot
study of cisplatin/vinorelbine +/- cetuximab as first-line treatment of advanced non small cell lung cancer (flex)

Conditions: Non Small Cell Lung Cancer (NSCLC)

Summary: the purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. overall survival will be taken as primary measure of efficacy.


Eligibility criteria:
inclusion criteria: * diagnosis of histologically or cytologically confirmed nsclc, stage iiib with documented malignant pleural effusion or stage iv * immunohistochemical evidence of egfr expression on tumor tissue * presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area exclusion criteria: * previous exposure to monoclonal antibodies, signal transduction inhibitors or egfr-targeting therapy * previous chemotherapy for nsclc * documented or symptomatic brain metastasis * superior vena cava syndrome contra-indicating hydration * previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

Keywords: cetuximab non small cell lung cancer lung cancer cisplatin/vinorelbine monoclonal antibody erbitux
a study of baricitinib (ly3009104) in children from 6 years to less than 18 years of age with alopecia areata

Conditions: Areata Alopecia; Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical

Summary: the main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. the study is divided into 4 periods, a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up period.


Eligibility criteria:
inclusion criteria: * enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old). * have severe areata alopecia (aa) for at least 1 year * diagnosis for at least 1 year * current aa episode of at least 6 months' duration * salt score ≥50% at screening and baseline * history of trial and failure with at least 1 available treatment (topical or other) for aa * history of psychological counseling related to aa * current episode of severe aa of less than 8 years. * note: participants who have severe aa for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years. exclusion criteria: * primarily "diffuse" type of aa (characterized by diffuse hair shedding). * are currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on aa. * are largely or wholly incapacitated permitting little or no self-care, such as being bedridden * have uncontrolled arterial hypertension * have had major surgery within 8 weeks prior to screening or will require major surgery during the study * have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking ip or interfere with the interpretation of data. * have a positive test for hepatitis b virus (hbv) infection * have hepatitis c virus (hcv) infection (positive for anti hepatitis c antibody with confirmed presence of hcv ribonucleic acid \[rna\]). * have evidence of human immunodeficiency virus (hiv) infection and/or positive hiv antibodies.